🚨 The Macro Trigger I’m Watching This Week: AI Biotech’s Big Funding Surge

Your Weekly Shortcut to Deeptech Investing — Trends, Startup Intel & Investor Playbooks for VCs & Angels in 5 Minutes or Less

Mar 27, 2025

∙ Paid

A futuristic biotech lab with AI-powered robotic arms analyzing DNA sequences on a large digital screen. Stacks of funding reports and investment charts are displayed on a sleek, high-tech desk. The atmosphere is dynamic, with glowing blue and green lights highlighting the innovation. The scene conveys a major breakthrough and excitement in AI-driven biotechnology funding.

AI biotech is exploding, and it’s a global race you can’t ignore. The U.S. just pumped $500 million more into AI-driven biotech this year via the NIH and DARPA (NIH Budget, March 2025), targeting game-changers like RNA vaccines and antibodies. Europe’s flexing too, with $8.5 billion poured into biotech startups in 2024 (Boston Consulting Group, 2024). AI’s slashing drug development timelines from years to weeks, and the stakes are sky-high—a $1 million investment today could balloon to $5 million by 2030.

Let’s dive into the cash flow, the leaders, the risks, and your playbook to cash in.

Keep reading with a 7-day free trial

Subscribe to Invest Deeptech to keep reading this post and get 7 days of free access to the full post archives.